Yahoo
ASX - Delayed Quote AUD

Dimerix Limited (DXB.AX)

0.2850 -0.0050 (-1.72%)
At close: 4:10:25 PM GMT+10
Chart Range Bar
Loading chart for DXB.AX
  • Previous Close 0.2900
  • Open 0.3050
  • Bid 0.2850 x --
  • Ask 0.2900 x --
  • Day's Range 0.2800 - 0.3100
  • 52 Week Range 0.1575 - 0.6650
  • Volume 2,999,082
  • Avg. Volume 2,174,932
  • Market Cap (intraday) 171.113M
  • Beta (5Y Monthly) 0.34
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0500
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date Sep 24, 1999
  • 1y Target Est 1.89

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease; as well as DMX-652 for the treatment of acute kidney injury. The company is headquartered in Fitzroy, Australia.

dimerix.com

15

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

DXB.AX
48.18%
S&P/ASX 200 [XJO] (^AXJO)
3.35%

1-Year Return

DXB.AX
40.63%
S&P/ASX 200 [XJO] (^AXJO)
2.03%

3-Year Return

DXB.AX
338.46%
S&P/ASX 200 [XJO] (^AXJO)
23.05%

5-Year Return

DXB.AX
17.13%
S&P/ASX 200 [XJO] (^AXJO)
19.71%

Analyst Insights

View More

Analyst Price Targets

1.89
1.89 Average
0.2850 Current
1.89 High

Statistics

View More

Valuation Measures

Annual
As of 9/2/2026
  • Market Cap

    174.12M

  • Enterprise Value

    158.19M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    40.02

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    36.36

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -29.36%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    6.35M

  • Net Income Avi to Common (ttm)

    -29.81M

  • Diluted EPS (ttm)

    -0.0500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    16.15M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -48.46M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: